Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapy

Apatinib — new third-line option for refractory gastric or GEJ cancer

Nature Reviews Clinical Oncology volume 13, pages 268–270 (2016)Cite this article

Subjects

Apatinib significantly improves both the progression-free survival (PFS) and overall survival in patients with advanced-stage gastric cancer who are refractory to two or more lines of chemotherapy. In the context of previous phase III trials of angiogenesis inhibitors for this disease, we discuss the role of apatinib, and the advantages and limitations of VEGFR-2 blockade in the advanced disease setting.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Li, J. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.63.5995 (2016).

  2. Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968–3976 (2011).

    Article  CAS  Google Scholar 

  3. Cunningham, D. et al. Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948). Presented at the European Cancer Congress 2015, Vienna, Austria (2015).

  4. Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 383, 31–39 (2014).

    Article  CAS  Google Scholar 

  5. Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro–oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224–1235 (2014).

    Article  CAS  Google Scholar 

  6. Hoeben, A. et al. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56, 549–580 (2004).

    Article  CAS  Google Scholar 

  7. Kowanetz, M. et al. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12, 5018–5022 (2006).

    Article  CAS  Google Scholar 

  8. de Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225–1233 (2012).

    Article  CAS  Google Scholar 

  9. Allegra, C. J. et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359–364 (2013).

    Article  CAS  Google Scholar 

  10. Joensuu, H. et al. Adjuvant treatments for triple-negative breast cancers. Ann. Oncol. 23,vi40–vi45 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Toru Aoyama and Takaki Yoshikawa are at the Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama 241–8515, Japan.,

    Toru Aoyama & Takaki Yoshikawa

Authors
  1. Toru Aoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takaki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takaki Yoshikawa.

Ethics declarations

Competing interests

T.Y. has received lecture fees from Abbott, Ajinomoto, Chugai, Eisai, Johnson & Johnson, Kaken, Lilly, Medtronic, Ono, Taiho, Takeda and Yakult. T.A. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aoyama, T., Yoshikawa, T. Apatinib — new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol 13, 268–270 (2016). https://doi.org/10.1038/nrclinonc.2016.53

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.53

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing